

**Reply: CMR Assessment of Myocyte Disarray in HCM: Matching Another Piece in the Puzzle**

Rina Ariga, MBBS DPhil,<sup>a</sup> Stefan Neubauer, MD<sup>a</sup> and Hugh Watkins, MD PhD<sup>a</sup>

<sup>a</sup> Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

**Funding:** RA is funded by a British Heart Foundation Clinical Research Training Fellowship (FS/12/32/29559). SN and HW acknowledge support from the National Institute for Health Research Oxford Biomedical Research Centre and the Oxford British Heart Foundation Centre of Research Excellence. SN and HW also acknowledge support from NHLBI grant U01HL117006-01A1.

**Disclosures**

All authors have nothing to disclose.

**Address for correspondence:**

Professor Hugh Watkins,  
Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK  
Telephone: +44 (0)1865 234657  
Fax: +44 (0)1865 234658  
Email: [hugh.watkins@rdm.ox.ac.uk](mailto:hugh.watkins@rdm.ox.ac.uk)

We thank Dr Radu Tanacli and colleagues for their interest in our recent paper on the identification of myocardial disarray in hypertrophic cardiomyopathy (HCM) (1). They emphasise the importance of quantifying fibrosis because in itself it might contribute to the appearance of disarray. Our study tried to account for both focal and diffuse fibrosis. Although extracellular volume (ECV) fraction is yet to be validated in HCM, it is the best biomarker of diffuse fibrosis available. But despite possible fibrosis induced-disarray, our effect remained even after factoring out fibrosis. There is much work to be done in validating fibrosis quantification by imaging with HCM histology. However, access to tissue is invariably difficult. They also suggest that oedema and inflammation could contribute to disarray. This is an intriguing possibility and requires further work.

## References

1. Ariga R, Tunnicliffe EM, Manohar SG et al. Identification of Myocardial Disarray in Patients With Hypertrophic Cardiomyopathy and Ventricular Arrhythmias. *J Am Coll Cardiol* 2019;73:2493-2502.